Are synthetic incretins associated with ischaemic optic neuropathy?
- PMID: 39955376
- PMCID: PMC11933427
- DOI: 10.1038/s41433-025-03718-0
Are synthetic incretins associated with ischaemic optic neuropathy?
Conflict of interest statement
Competing interests: VG declares no competing interests. Professor Mollan reports consultancy fees (Invex Therapeutics; Velux foundation); advisory board fees (Invex therapeutics; Gensight) and speaker fees (Heidelberg engineering; Chugai-Roche Ltd; Allergan; Santen; Chiesi; and Santhera).
References
-
- Tichy EM, Hoffman JM, Tadrous M, Rim MH, Cuellar S, Clark JS, et al. National trends in prescription drug expenditures and projections for 2024. Am J Health Syst Pharm. 2024;81:583–98. - PubMed
-
- Semaglutide for managing overweight and obesity. Technology appraisal guidance (TA875) The National Institute for Health and Care Excellence. March 2023. Available at: https://www.nice.org.uk/guidance/ta875/chapter/1-Recommendations [Last accessed 31st Janurary, 2025].
-
- Mollan SP. Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy. JAMA Ophthalmol. 2024;142:740–1. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
